LRMR
Larimar Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.12
+6.80%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -64.6%
- EBIT
- -64.9%
- EPS
- -27.6%
- Free cash flow
- -68.6%
- Operating cash flow
- -69.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +21.0%
- EPS
- +30.5%
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- -89.8%
- Net income
- —
- EPS
- -72.0%
- Free cash flow
- -59.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026